Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY

Citation
Rhee JJ, Jardine MJ, Chertow GM, Mahaffey KW. Diabetes Obes Metab 2020;22(Suppl 1):46–54.